RT Journal Article
SR Electronic
T1 Aggressive Antipyretics in CNS Malaria: Study Protocol of a Randomized-Controlled Trial Assessing Antipyretic Efficacy and Parasite Clearance Effects (Malaria FEVER Study)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.05.22274544
DO 10.1101/2022.05.05.22274544
A1 Chilombe, Moses
A1 McDermott, Michael
A1 Seydel, Karl B.
A1 Mathews, Manoj
A1 Mwenechanya, Musaku
A1 Birbeck, Gretchen L.
YR 2022
UL http://medrxiv.org/content/early/2022/05/09/2022.05.05.22274544.abstract
AB Background Despite ongoing eradication efforts, malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neurodisability. Evidence indicates that among children with CNS malaria, a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted, at least among children with complicated malaria who are at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. In this clinical trial of aggressive antipyretic therapy, children hospitalized with CNS malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature ≥ 38.5°C) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours. This proof-of-concept study will determine whether aggressive antipyretic therapy results in a lower mean maximum temperature relative to usual care.Methods We will enroll 284 participants from three settings at Queen Elizabeth Central Hospital in Blantyre, Malawi; at the University Teaching Hospitals Children’s Hospital in Lusaka, Zambia and at Chipata Central Hospital, Chipata, Zambia. Parents or guardians must provide written informed consent. Eligible participants are 2-11 years with evidence of P. falciparum malaria infection by peripheral blood smear or rapid diagnostic test with CNS symptoms associated with malaria. Eligible children will receive treatment allocation as determined by randomization and will be assigned to treatment groups with 1:1 allocation using blocked randomization.Discussion The clinical trial proposed here seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic use involving two antipyretics and prophylactic administration while also taking advantage of a relatively new method for quantifying total parasite burden (HRP2 quantification) to further characterize malaria severity and elucidate the impact of antipyretics on parasite sequestration and clearance. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature during CNS malaria, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.Trial registration This trial is registered with ClinicalTrial.gov (NCT03399318) and with the Pan African Clinical Trials Registry (PACTR201804003255157)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov (NCT03399318)Funding StatementThe study was funded by the US NIH, NIHR01NS102176. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In addition to the oversight provided at each site by the local study monitors, the study has been approved by the following Institutional Review Boards. 1. The University of Zambia Biomedical Research Ethics Committee FWA00000338 (UNZA BREC)- initially approved on 17 August 2018, renewed on 16 November 2021, approval number 003-06-18. 2. The University of Malawi College of Medicine Research Ethics Committee FWA00011868 (COMREC)- initially approved on 08 November 2017, renewed on 09 November 2021, approval number P.10/17/2298 3. The University of Rochester Research Subjects Review Board FWA00009386 (RSRB) - initially approved 27 April 2017, renewed on 16 November 2021, approval number RSRB 000667717 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completionPIPrincipal InvestigatorCMCerebral MalariaM/SMMalaria and SeizuresHRP2Histidine Rich ProteinqPCquantitative Parasite CountAUCArea under CurvePRWPediatric Research Ward at Queen Elizabeth Hospital in BlantyrePICUPediatric Intensive Care Ward (PICU) at University Teaching Hospital in Lusaka, ZambiaURUniversity of RochesterBCHBoston Children’s HospitalMSUMichigan State UniversityLSMLocal Study MonitorDSMBData and Safety Monitoring BoardSAEsSerious Adverse EventsUNZA BRECThe University of Zambia’s Biomedical Research Ethics CommitteeCOMRECThe University of Malawi’s College of Medicine Research Ethics CommitteeRSRBThe University of Rochester’s Research Subjects Review Board